Generic Champix ( Varenicline )

Buy Generic Champix (Varenicline) without prescription in Canada

In our Canadian pharmacy, you can buy Champix (Varenicline) without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Champix (varenicline tartrate) is a smoking cessation aid specifically developed to help motivated adults stop smoking. It works as a partial agonist at alpha‑4 beta‑2 nicotinic acetylcholine receptors in the brain, where it both stimulates these receptors (reducing nicotine craving and withdrawal symptoms) and blocks nicotine from binding to them (diminishing the rewarding and reinforcing effects of smoking). Champix is most effective when used in combination with supportive counselling and a structured quit program.

Usual adult dose: The recommended dosing begins with a 1‑week titration: Days 1‑3: 0.5 mg once daily; Days 4‑7: 0.5 mg twice daily; Day 8 to end of treatment: 1 mg twice daily. The patient should set a date to stop smoking, and Champix dosing should usually start 1‑2 weeks before this date. Treatment is typically continued for 12 weeks; for patients who successfully quit, an additional 12‑week course (1 mg twice daily) may be considered for maintenance of abstinence. A gradual quit approach (reducing smoking over 12 weeks, then quitting) is an alternative for patients unable or unwilling to quit abruptly.

Dosage form: Film‑coated tablets: 0.5 mg (white, capsular‑shaped) and 1 mg (light blue, capsular‑shaped). Available as an Initiation Pack (containing both strengths for dose titration) and a Continuation Pack (1 mg tablets).

Onset of action: Steady‑state plasma concentrations are reached within 4 days of repeat dosing. Craving and withdrawal symptom reduction may begin during the first week of treatment; maximal therapeutic effect is typically achieved after several weeks of abstinence‑focused therapy.

Duration of action: Approximately 24 hours, permitting twice‑daily maintenance dosing. The elimination half‑life is approximately 24 hours.

Alcohol recommendation: Alcohol consumption should be avoided during treatment with Champix. Drinking alcohol may increase the risk of developing neuropsychiatric symptoms, including agitation, aggression, and depressed mood. Patients should limit alcohol intake until they know how Champix affects them.

Most common side effects: Nausea, vomiting, abnormal dreams, insomnia, headache, constipation, and flatulence. Nausea is the most frequently reported adverse effect, occurring in approximately 30% of patients; it is usually mild to moderate and diminishes over time.

Would you like to try Champix (Varenicline) without a prescription?

General Information about Champix (Varenicline)

• INN (International Nonproprietary Name): Varenicline tartrate
• Brand names available in Canada: Champix® (Pfizer Canada ULC), APO‑Varenicline (Apotex Inc.), TEVA‑Varenicline (Teva Canada Limited), Sandoz Varenicline (Sandoz Canada Inc.), PMS‑Varenicline (Pharmascience Inc.), NRA‑Varenicline (Nora Pharma Inc.), MINT‑Varenicline (Mint Pharmaceuticals), JAMP‑Varenicline (JAMP Pharma Corporation), GD‑Varenicline (GenMed, a division of Pfizer Canada ULC), and other generic manufacturers.
• ATC code: N07BA03 (drugs used in nicotine dependence)
• Dosage forms and strengths: Film‑coated tablets: 0.5 mg and 1.0 mg (as varenicline tartrate). Initiation Pack: contains both 0.5 mg and 1 mg tablets for the 1‑week dose‑titration period. Continuation Pack: contains 1 mg tablets.
• Manufacturers in Canada: Pfizer Canada ULC, Apotex Inc., Teva Canada Limited, Sandoz Canada Inc., Pharmascience Inc., Nora Pharma Inc., Mint Pharmaceuticals, JAMP Pharma Corporation, and various generic manufacturers.
• Registration status in Canada: Approved by Health Canada (Notice of Compliance: 2007/01/24; first marketed: 2007/04).
• OTC / Rx classification: Prescription only (Rx). Schedule I drug. Champix is not available over the counter and requires a valid prescription from a licensed Canadian healthcare professional.

Mechanism of Action and Pharmacology

Varenicline is a selective, partial agonist of the alpha‑4 beta‑2 (α4β2) nicotinic acetylcholine receptor subtype, which is the principal receptor mediating nicotine dependence. Varenicline binds with high affinity to this receptor, producing a dual pharmacological effect: it acts as a partial agonist, stimulating the receptor to a lesser degree than nicotine (thereby reducing craving and withdrawal symptoms during abstinence), and as an antagonist in the presence of nicotine by blocking nicotine binding (thereby reducing the rewarding and reinforcing dopaminergic effects of smoking). This combined agonist‑antagonist activity attenuates the mesolimbic dopamine response to nicotine and helps break the cycle of addiction.

Varenicline is rapidly absorbed after oral administration, with peak plasma concentrations occurring approximately 3‑4 hours after dosing. Steady‑state plasma levels are achieved within 4 days of twice‑daily dosing. The drug undergoes minimal hepatic metabolism (less than 10% of the dose is metabolized); it does not inhibit or induce cytochrome P450 enzymes (IC50 > 6400 ng/mL for CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4/5). Approximately 92% of an oral dose is excreted unchanged in the urine. The elimination half‑life is approximately 24 hours. Plasma protein binding is low (≤ 20%).

In patients with severe renal impairment (creatinine clearance < 30 mL/min), varenicline clearance is reduced by approximately 60%, and dose adjustment is required. In patients with moderate renal impairment (CrCl 30‑50 mL/min) who experience intolerable adverse effects, dose reduction to 1 mg once daily may be considered.

Indications

• Smoking‑cessation treatment in adults, in conjunction with smoking‑cessation counselling.
• For motivated adult smokers who are willing to quit (abrupt quit approach) or who are not able or willing to quit abruptly (gradual quit approach).
• Maintenance of abstinence in patients who have successfully quit smoking after an initial 12‑week treatment course.
• Champix is not recommended for use in children and adolescents under 18 years of age.

Important Warnings and Precautions

At‑risk groups

• Pregnancy: Champix should not be taken during pregnancy. It is unknown whether Champix will harm an unborn baby. It is best to stop smoking before becoming pregnant. Women of childbearing potential should use effective contraception during treatment.
• Breastfeeding: It is not known whether varenicline is excreted in human milk. A decision must be made whether to discontinue breastfeeding or discontinue the drug, considering the importance of the medication to the mother.
• Paediatrics (< 18 years): Safety and efficacy have not been established in children and adolescents under 18. Champix is not recommended for this age group.
• Elderly: No dosage adjustment is necessary based on age alone. However, elderly patients are more likely to have decreased renal function; prescribers should consider renal status.
• Renal impairment: No dosage adjustment is needed for mild to moderate renal impairment (CrCl > 30 mL/min). For severe renal impairment (CrCl < 30 mL/min), the recommended dose is 1 mg once daily, starting at 0.5 mg once daily for the first 3 days.
• Hepatic impairment: No dosage adjustment is required in patients with mild to moderate hepatic impairment.
• Mental health disorders: Patients with a history of depression or other mental health problems should inform their healthcare provider before starting treatment. Champix has been associated with neuropsychiatric symptoms including changes in behaviour, hostility, agitation, depressed mood, and suicidal ideation. These symptoms have occurred in patients with and without pre‑existing psychiatric conditions. Close monitoring is essential.
• Cardiovascular disease: Champix should be used with caution in patients with cardiovascular (heart or blood vessel) problems. There may be a small increased risk of cardiovascular events, including myocardial infarction. In patients with stable cardiovascular disease, Champix did not demonstrate a significant increase in cardiovascular adverse events.
• Seizures: Patients with a history of seizures should inform their healthcare provider before starting Champix.
• Diabetes mellitus: Champix can potentially affect blood‑sugar regulation; more frequent blood‑glucose monitoring may be required. Insulin and other antidiabetic medication doses may need adjustment once smoking has ceased.
• Concomitant nicotine replacement therapy (NRT): The combination of Champix and NRT is not recommended; it may result in more side effects than Champix alone.
• Allergy: Do not take Champix if you are allergic (hypersensitive) to varenicline tartrate or any of the other ingredients.

Driving and alcohol

Varenicline may affect mental alertness and physical coordination. Patients should not engage in potentially hazardous tasks, such as driving a car or operating dangerous machinery, until they are sure of the effect varenicline has on their mental alertness. Alcohol consumption should be avoided during treatment because it may increase the risk of developing neuropsychiatric symptoms, including hostility, agitation, aggression, and depressed mood. Patients should limit alcohol intake until they know how Champix affects them.

Dosage Instructions

• Standard titration (abrupt quit): Days 1‑3: 0.5 mg once daily; Days 4‑7: 0.5 mg twice daily; Day 8 to end of treatment: 1 mg twice daily. The patient should set a quit date 1‑2 weeks after starting Champix. Duration: 12 weeks.
• Maintenance therapy: For patients who successfully quit at the end of 12 weeks, an additional 12‑week course at 1 mg twice daily may be prescribed to maintain abstinence.
• Gradual quit approach: For patients unable or unwilling to quit abruptly, reduce smoking during the first 12 weeks of treatment, aim to quit by the end of that period, and continue treatment for an additional 12 weeks (total 24 weeks).
• Dose reduction for intolerable side effects: If patients cannot tolerate 1 mg twice daily, the dose may be reduced temporarily or permanently to 0.5 mg twice daily.
• Renal impairment: For severe renal impairment (CrCl < 30 mL/min), start at 0.5 mg once daily for 3 days, then increase to 1 mg once daily. For moderate renal impairment (CrCl 30‑50 mL/min) with intolerable adverse effects, reduce to 1 mg once daily.
• Administration: Swallow tablets whole with a full glass of water, with or without food. Taking tablets with food may help reduce nausea. Do not crush or chew the tablets.
• Missed dose: If a dose is missed, take it as soon as remembered unless it is close to the next scheduled dose (within 4 hours). Do not double the dose to make up for a missed dose.
• Dose tapering at end of treatment: In patients at high risk of relapse, gradual dose tapering may be considered.

Side Effects and Contraindications

• Most common side effects (frequency ≥ 5%): Nausea (28‑30%), insomnia (18‑19%), abnormal dreams (13‑18%), headache (15‑19%), vomiting (5%), constipation (8%), flatulence (6‑9%), dysgeusia (altered taste), and dry mouth.
• Less common side effects: Somnolence, fatigue, increased appetite, weight gain, upper respiratory tract infection, nasopharyngitis, diarrhoea, dyspepsia, abdominal pain, arthralgia, myalgia, dizziness, irritability, anxiety, depression, and rash.
• Serious adverse reactions: Neuropsychiatric symptoms including changes in behaviour or thinking, hostility, agitation, aggression, depressed mood, and suicidal thoughts or actions. These events have occurred in patients with and without pre‑existing psychiatric disorders and during treatment or shortly after discontinuation. Patients and caregivers should immediately report any unusual changes in mood or behaviour.
• Cardiovascular events: A small increased risk of cardiovascular adverse events (including myocardial infarction) has been observed in some pooled analyses. In patients with stable cardiovascular disease, no significant increase was demonstrated.
• Hypersensitivity reactions: Angioedema (swelling of the face, mouth, and throat that can cause trouble breathing) and serious skin reactions, including Stevens‑Johnson syndrome and erythema multiforme. Patients should discontinue Champix and seek immediate medical attention if these symptoms occur.
• Seizures: Seizures have been reported in patients with and without a history of seizures.
• Sleepwalking: Cases of sleepwalking have been reported with varenicline use.
• Contraindications: Hypersensitivity to varenicline tartrate or any component of the formulation. Concomitant use with nicotine replacement therapy (NRT) is not recommended. Pregnancy. Breastfeeding.

Drug Interactions

• Nicotine replacement therapy (NRT): Concomitant use of Champix with nicotine patches, gum, lozenges, or inhalers is not recommended. The combination has not been shown to improve quit rates and may increase the incidence of adverse effects.
• Alcohol: Drinking alcohol during treatment with Champix may increase the risk of developing neuropsychiatric symptoms. Alcohol intake should be limited or avoided.
• Drugs affected by smoking cessation: Smoking induces CYP1A2; upon cessation, plasma levels of drugs metabolized by CYP1A2 (e.g., theophylline, warfarin, insulin, some antipsychotics) may increase, necessitating dose reductions. Monitoring is recommended.
• Cytochrome P450 enzymes: Varenicline does not inhibit or induce CYP450 enzymes and does not affect the pharmacokinetics of drugs metabolized by CYP enzymes (IC50 > 6400 ng/mL for CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4/5). Less than 10% of varenicline is metabolized; CYP P450 inhibitors or inducers are unlikely to affect varenicline pharmacokinetics.
• Drugs cleared by renal secretion: In vitro studies indicate that varenicline does not inhibit renal transport proteins at therapeutic concentrations; drugs cleared by renal secretion are unlikely to be affected.
• Cimetidine: Cimetidine, an inhibitor of renal tubular secretion, may decrease the renal clearance of varenicline, but dosage adjustment is not typically required.

Practical Advice

• Administration: Take Champix tablets with a full glass of water, with or without food. Taking the medication with food may help reduce nausea, the most common side effect. Swallow tablets whole; do not crush or chew.
• Setting a quit date: Select a target quit date 1‑2 weeks after starting Champix. Use the time before the quit date to prepare mentally and practically for smoking cessation.
• Counselling and support: Champix is most effective when combined with a structured smoking‑cessation support program that includes education, behavioural counselling, and social support. Many Canadian provinces offer free quitlines and cessation counselling.
• Monitoring: Regular follow‑up visits are recommended to assess smoking status, treatment tolerability, and the emergence of neuropsychiatric symptoms. Patients with diabetes should monitor blood glucose more frequently during treatment and after quitting. Close family and friends should be informed of the quit attempt and asked to watch for changes in mood or behaviour.
• Storage: Store at room temperature (15‑30 °C) in a dry place. Protect from moisture and light. Keep out of reach and sight of children.
• Managing nausea: Nausea is common but often diminishes with continued use. Taking the medication after meals with a full glass of water may help. Persistent nausea that interferes with daily activities should be reported to the healthcare provider; dose reduction to 0.5 mg twice daily may be appropriate.
• Relapse prevention: The risk of relapse is highest in the period immediately after treatment ends. Gradual dose tapering may be considered for high‑risk patients. Patients who relapsed after treatment or who did not succeed in quitting may benefit from another quit attempt with Champix.
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Bupropion (Zyban®): An oral antidepressant that reduces nicotine cravings. It is a non‑nicotine pill requiring a prescription. Head‑to‑head trials demonstrate that varenicline achieves significantly higher continuous abstinence rates at 6 months compared with bupropion, although no significant difference was observed at 12 months.
• Nicotine Replacement Therapy (NRT) — Patch: A transdermal patch that provides a steady, controlled release of nicotine to reduce withdrawal symptoms. Available without a prescription in Canada. Nicotine patches are effective for smoking cessation and may be used alone or in combination with short‑acting NRT.
• Nicotine Replacement Therapy (NRT) — Gum and Lozenge: Short‑acting oral NRT products that provide rapid relief from acute cravings. Available without a prescription. They can be used alone or in combination with a nicotine patch.
• Nicotine Inhaler: A device that delivers nicotine vapour into the mouth and throat, satisfying both the pharmacological craving and the hand‑to‑mouth behavioural ritual of smoking. Available without a prescription.
• Nortriptyline: A tricyclic antidepressant that has demonstrated efficacy for smoking cessation; used off‑label. Nortriptyline may be considered when first‑line therapies are contraindicated or have failed.
• Combination pharmacotherapy: In some cases, a healthcare provider may recommend combining a nicotine patch with a short‑acting NRT (gum or lozenge) or bupropion with NRT. Combination therapy may be considered for smokers who have failed monotherapy. Note that Champix with NRT is not currently recommended.
• Behavioural support alone: For patients who cannot or prefer not to use pharmacotherapy, structured behavioural counselling (individual, group, or telephone‑based) alone can be effective, though quit rates are lower than with medication‑assisted attempts.

Clinical Efficacy

The efficacy of varenicline for smoking cessation has been established in numerous randomized, placebo‑controlled clinical trials and confirmed by comprehensive systematic reviews and network meta‑analyses. In pooled data from 27 randomized controlled trials involving over 12,000 participants, varenicline more than doubled the odds of continuous or sustained abstinence at 24 weeks or longer compared with placebo (risk ratio [RR] 2.24, 95% CI 2.06‑2.43). The absolute abstinence rate was approximately 25% for varenicline versus 11% for placebo.

Head‑to‑head comparisons demonstrate that varenicline is superior to bupropion (RR 1.39, 95% CI 1.25‑1.54) and more effective than nicotine replacement therapy (RR 1.25, 95% CI 1.14‑1.37) for continuous abstinence at 24 weeks. A Canadian systematic review and network meta‑analysis (DSEN, 2014) confirmed that varenicline 1 mg twice daily showed significantly higher continuous abstinence rates at 6 months compared with both placebo and bupropion 150 mg twice daily, with no significant difference at 12 months.

The EAGLES trial, a large (over 8,000 participants) randomized, double‑blind, triple‑dummy, placebo‑ and active‑controlled trial, evaluated the neuropsychiatric safety of varenicline versus bupropion, nicotine patch, and placebo in smokers with and without a history of psychiatric disorders. Varenicline demonstrated superior efficacy to bupropion (odds ratio 1.58 for weeks 9‑12 abstinence) and comparable efficacy to nicotine patch. No significant increase in moderate‑to‑severe neuropsychiatric adverse events was observed for varenicline relative to placebo.

The most common adverse effect in clinical trials was nausea, occurring in approximately 28‑30% of participants, with a number needed to harm (NNH) of approximately 5. Nausea was typically mild to moderate in severity and tended to diminish over the course of treatment. Other common adverse effects included insomnia (18%), abnormal dreams (13%), and headache (15%).

Clinical guidelines from the Canadian Action Network for the Advancement, Dissemination and Adoption of Practice‑informed Tobacco Treatment (CAN‑ADAPTT) recommend varenicline as a first‑line pharmacotherapy for smoking cessation, particularly for smokers who are highly dependent or who have failed other treatments.

Important:

Champix (varenicline) is a prescription medication that should be used only under the supervision of a qualified healthcare professional. It must always be used in combination with smoking‑cessation counselling and support. Serious neuropsychiatric symptoms, including changes in behaviour, agitation, hostility, depressed mood, suicidal thoughts, or attempts at suicide, have been reported in patients taking Champix. These events have occurred in individuals with and without pre‑existing mental health conditions. If you, your family, or caregiver notice any unusual changes in mood, behaviour, or thinking, stop taking Champix immediately and contact your healthcare provider or seek emergency medical attention. Alcohol intake should be limited during treatment, as it may increase the risk of these symptoms. Champix is not recommended during pregnancy or breastfeeding. Do not combine Champix with nicotine replacement therapy. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Champix - Shipping across Canada